Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of JSKN033 versus investigator's choice chemotherapy in recurrent or metastatic cervical cancer after platinum chemotherapy and PD-1/PD-L1 inhibitor failure
CTR20263455Phase 3Active
- Sponsor
- Kanion Pharmaceutical
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of JSKN033 in Cervical Cancer (CC), sponsored by Kanion Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
JSKN033
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20263455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263455.